Credit Suisse analyst Daniel Oppenheim downgrades AZEK Co (NYSE:AZEK) from Outperform to Neutral.
Petros Pharmaceuticals Provides Letter To Shareholders; Developing and executing on a new pathway toward non-prescription for lead product; Outlines Milestones For STENDRA
To our valued shareholders,As we approach the fourth quarter of 2023, Petros has been quietly undergoing a change in approach to our business. As we have previously announced, our evolving focus has shifted from
